GSC
VRTX icon

Grey Street Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Grey Street Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$18.5M Buy
44,186
+7,621
+21% +$3.22M 2.5% 6
2023
Q4 		$14.9M Buy
36,565
+8,785
+32% +$3.25M 7.08% 2
2023
Q3 		$9.66M Sell
27,780
-168
-0.6% -$58.8K 5.54% 3
2023
Q2 		$9.84M Buy
27,948
+21,243
+317% +$7.16M 5.21% 3
2023
Q1 		$2.11M Buy
+6,705
New +$2.01M 1.49% 18

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Grey Street Capital's VRTX Position: Q1 2024 in Review

Grey Street Capital increased its Vertex Pharmaceuticals (VRTX) stake by 21% in Q1 2024, buying an estimated $3.22M and bringing the position to 44,186 shares worth $18.5M. The position accounts for 2.5% of the portfolio, ranked #6.

Grey Street Capital first reported a position in VRTX in Q1 2023 and has held it in 5 quarters since. 1,495 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

  • Grey Street Capital held 44,186 shares of Vertex Pharmaceuticals worth $18.5M as of Q1 2024.
  • Grey Street Capital bought 7,621 Vertex Pharmaceuticals shares in Q1 2024, an estimated $3.22M.
  • Vertex Pharmaceuticals made up 2.5% of Grey Street Capital's portfolio in Q1 2024, its #6 holding.
  • Grey Street Capital first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 5 quarters since.
  • 1,495 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Grey Street Capital's 13F filing for Q1 2024, filed 9 Aug 2024.